- Home
- NQP vs ATAI Comparison
NQP vs ATAI Comparison
Compare NQP & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NQP
- ATAI
- Stock Information
- Founded
- NQP 1990
- ATAI 2018
- Country
- NQP United States
- ATAI Germany
- Employees
- NQP N/A
- ATAI N/A
- Industry
- NQP Trusts Except Educational Religious and Charitable
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- NQP Finance
- ATAI Health Care
- Exchange
- NQP Nasdaq
- ATAI Nasdaq
- Market Cap
- NQP 413.9M
- ATAI 444.7M
- IPO Year
- NQP N/A
- ATAI 2021
- Fundamental
- Price
- NQP $11.22
- ATAI $4.54
- Analyst Decision
- NQP
- ATAI Strong Buy
- Analyst Count
- NQP 0
- ATAI 3
- Target Price
- NQP N/A
- ATAI $13.33
- AVG Volume (30 Days)
- NQP 58.4K
- ATAI 5.3M
- Earning Date
- NQP 01-01-0001
- ATAI 08-14-2025
- Dividend Yield
- NQP 3.21%
- ATAI N/A
- EPS Growth
- NQP N/A
- ATAI N/A
- EPS
- NQP N/A
- ATAI N/A
- Revenue
- NQP N/A
- ATAI $2,309,000.00
- Revenue This Year
- NQP N/A
- ATAI $661.36
- Revenue Next Year
- NQP N/A
- ATAI N/A
- P/E Ratio
- NQP N/A
- ATAI N/A
- Revenue Growth
- NQP N/A
- ATAI 510.85
- 52 Week Low
- NQP $9.65
- ATAI $1.03
- 52 Week High
- NQP $11.89
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- NQP 72.53
- ATAI 60.91
- Support Level
- NQP $10.83
- ATAI $4.23
- Resistance Level
- NQP $11.03
- ATAI $4.65
- Average True Range (ATR)
- NQP 0.08
- ATAI 0.37
- MACD
- NQP 0.04
- ATAI -0.04
- Stochastic Oscillator
- NQP 97.96
- ATAI 44.91
About NQP Nuveen Pennsylvania Quality Municipal Income Fund
Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.